Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. David M. Reese, M.D., Amgen's executive vice president of Research and Development, will lead the presentation. Interested parties can access the live audio broadcast via Amgen's website along with other investor and medical conference presentations. The event's webcast will be archived for 90 days. Amgen focuses on developing innovative therapeutics to address serious medical needs, utilizing advanced human genetics to enhance health outcomes.
Amgen and Five Prime Therapeutics announced an acquisition agreement where Amgen will acquire Five Prime for $38.00 per share, totaling an equity value of approximately $1.9 billion. This strategic acquisition aims to enhance Amgen's oncology portfolio with Five Prime's innovative therapies, particularly the bemarituzumab antibody, which shows promise in treating advanced gastric cancer. The transaction is projected to close by the end of Q2 2021, subject to customary conditions.
Amgen (NASDAQ:AMGN) declared a $1.76 per share dividend for Q2 2021, set to be paid on June 8, 2021, to stockholders of record by May 17, 2021. The company highlights its commitment to developing innovative therapies focusing on high unmet medical needs. Amgen's legacy in biotechnology since 1980 has positioned it among leading independent biotech firms, striving for improved health outcomes globally.
Amgen announced that data from a Phase 3 study published in JAMA highlights the efficacy of BLINCYTO (blinatumomab) in pediatric patients with high-risk B-cell precursor acute lymphoblastic leukemia (B-ALL). After a median follow-up of 22.4 months, 69% of patients treated with BLINCYTO were alive and event-free, compared to 43% with chemotherapy. The 36-month overall survival rate was 81.1% for BLINCYTO versus 55.8% for chemotherapy. Serious adverse events were significantly lower in the BLINCYTO group (24.1% vs. 43.1%). These results suggest BLINCYTO may be a new standard of care for this aggressive disease.
Amgen and AstraZeneca announced positive results from the NAVIGATOR Phase 3 trial for tezepelumab as a potential first-in-class treatment for severe asthma. The trial demonstrated a 56% reduction in the annualized asthma exacerbation rate (AAER) when added to standard care over 52 weeks compared to placebo (p<0.001). Key secondary endpoints also showed significant improvements in lung function and quality of life. There were no significant safety differences between tezepelumab and placebo. Tezepelumab is a promising option for patients with severe asthma, regardless of eosinophil count.
Amgen (NASDAQ:AMGN) will participate in the Cowen 41st Annual Virtual Healthcare Conference on March 4, 2021, at 12:50 p.m. ET. Presenters include Murdo Gordon, EVP of Global Commercial Operations, and Peter H. Griffith, CFO. The presentation will be accessible live via Amgen's website and available as a replay for at least 90 days. Amgen is dedicated to developing innovative therapies for serious illnesses through advanced genetics and biotechnology. The company aims to address high unmet medical needs and improve health outcomes globally.
Amgen will host a webcast for investors on February 26, 2021, at 1:00 p.m. ET, during the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The call will feature David M. Reese, M.D., discussing the tezepelumab Phase 3 NAVIGATOR study results for severe asthma patients, alongside clinical trial investigators. The live audio will be accessible via Amgen's website, with an archive available for 90 days post-event. Amgen focuses on innovative therapeutics and addressing significant medical needs.
Amgen announced the submission of a supplemental New Drug Application (sNDA) for Otezla (apremilast) to the FDA for treating adults with mild-to-moderate plaque psoriasis. The submission is based on positive Phase 3 ADVANCE trial results, showing statistically significant improvement in the primary endpoint over placebo. The study involved 595 patients, with Otezla demonstrating effectiveness in various secondary endpoints. Otezla is already approved for moderate-to-severe plaque psoriasis and has been used by over 250,000 patients in the U.S. since its 2014 approval.
Amgen announced that the FDA has granted Priority Review for sotorasib, a treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This designation signifies potential significant improvements in treatment options. The Prescription Drug User Fee Action (PDUFA) date is set for Aug. 16, 2021, four months earlier than the standard review. The New Drug Application is based on Phase 2 results from the CodeBreaK 100 trial, which enrolled 126 patients. Sotorasib has also received Breakthrough Therapy Designation in the U.S. and China.
Amgen (NASDAQ:AMGN) announced that Greg Friberg, its global oncology head, will participate in a fireside chat during the Guggenheim Healthcare Talks 2021 Oncology Day on February 12 at 12:30 p.m. ET. The live audio of the event will be available online for media, investors, and the public. Interested parties can access the webcast through Amgen's website, and it will be archived for 90 days post-event. Amgen is dedicated to developing innovative therapeutics for serious illnesses, focusing on high unmet medical needs and leveraging advanced human genetics.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
